Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation

Biomedicine and Pharmacotherapy

Volumn 68, Issue 6, 2014, Pages 751-756

  Yuan, Huaqin ^a   Cai, Peifen ^a   Li, Qian ^a   Wang, Weicheng ^a   Sun, Yang ^b   Xu, Qiang ^b   Gu, Yanhong ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

Antitumor immunity; Axitinib; Myeloid derived suppressor cells; Signal transducer and activator of transcription 3; Vascular endothelial growth factor receptor

Indexed keywords

AXITINIB; CD8 ANTIGEN; STAT3 PROTEIN; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; STAT3 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER GROWTH; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; KIDNEY CARCINOMA; METASTASIS; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOSYNTHESIS; CARCINOMA, RENAL CELL; DRUG EFFECTS; DRUG SCREENING; IMMUNOLOGY; KIDNEY NEOPLASMS; METABOLISM; PROCEDURES; TUMOR CELL LINE;

ANIMALS; CARCINOMA, RENAL CELL; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; FEMALE; IMIDAZOLES; INDAZOLES; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; MYELOID CELLS; STAT3 TRANSCRIPTION FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908089640     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.07.002     Document Type: Article

References (32)

1. Hu-Lowe D.D., Zou H.Y., Grazzini M.L., et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008, 14:7272-7283.
2. Bhargava P., Robinson M.O. Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr Oncol Rep 2011, 13:103-111.
3. Rini B.I., Escudier B., Tomczak P., et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378:1931-1939.
4. Gallina G., Dolcetti L., Serafini P., et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006, 116:2777-2790.
5. Dmitry I., Gabrilovichand Srinivas N. Myeloid-derived-suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009, 9(3):162-174.
6. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009, 182:4499-4506.
7. Gabrilovich D.I., Bronte V., Chen S.H., et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res 2007, 67:425.
8. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9:162-174.
9. Rodriguez P.C., Hernandez C.P., Quiceno D., et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 2005, 202:931-939.
10. Nagaraj S., Gupta K., Pisarev V., et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007, 13:828-835.
11. Kusmartsev S., Gabrilovich D.I. Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J Leukoc Biol 2003, 74:186-196.
12. Bronte V., Serafini P., Apolloni E., et al. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J Immunother 2001, 24:431-446.
13. Marigo I., Dolcetti L., Serafini P., et al. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008, 222:162-179.
14. Suzuki E., Kapoor V., Jassar A.S., et al. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005, 11:6713-6721.
15. Ko H.J., Kim Y.J., Kim Y.S., et al. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res 2007, 67:7477-7486.
16. Yu H., Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004, 4:97-105.
17. Horiguchi A., Oya M., Shimada T., et al. Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol 2002, 168:762-765.
18. Gao S.P., Mark K.G., Leslie K., et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007, 117:3846-3856.
19. Cheng P., Corzo C.A., Luetteke N., et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008, 205:2235-2249.
20. Nefedova Y., Nagaraj S., Rosenbauer A., et al. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res 2005, 65:9525-9535.
21. Nefedova Y., Huang M., Kusmartsev S., et al. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol 2004, 172:464-474.
22. Kortylewski M., Kujawski M., Wang T., et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005, 11:1314-1321.
23. Wang L., Gu Y., Shu Y., et al. Integrin alpha6 (high) cell population functions as an initiator in tumorigenesis and relapse of human liposarcoma. Mol Cancer Ther 2011, 10:2276-2286.
24. TatsumiT, Kierstead L.S., Ranieri E., et al. Disease-associated bias inT helper type 1 (Th1)/Th2 CD4 (+) Tcell responses againstMAGE-6 in HLA-DRB10401 (+) patients with renal cell carcinoma or melanoma. J Exp Med 2002, 196:619-628.
25. Tatsumi T., Herrem C.J., Olson W.C., et al. Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res 2003, 63:4481-4489.
26. Tatsumi T., Kierstead L.S., Ranieri E., et al. MAGE-6 encodes HLA-DRh1*0401-presented epitopes recognized by CD4+T cells from patients with melanoma or renal cell carcinoma. Clin Cancer Res 2003, 9:947-954.
27. Vieweg J., Su Z., Dahm P., Kusmartsev S. Reversal of tumor-mediated immunosuppression. Clin Cancer Res 2007, 13:727-732.
28. Gabrilovich D.I., Ishida T., Nadaf S., et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999, 5:2963-2970.
29. Hideyuki Akaza, Tomofusa, Fukuyama Axitinib for the treatment of advanced renal cell carcinoma. Expert Opin Pharmacother 2014, 15:283-297.
30. Kusmartsev S., Nagaraj S., Gabrilovich D.I. Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol 2005, 175:4583-4592.
31. Kujawski M., Kortylewski M., Lee H.Y., et al. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 2008, 118:3367-3377.
32. Wang T., Niu G., Kortylewski M., et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004, 10:48-54.